Randomized study of the efficacy of monoclonal antibodies in patients with refractory psoriasis

BACKGROUND: The main vector of psoriasis therapy is suppression proliferative activity keratinocytes, normalization their differentiation, neutralization immune inflammation in the dermis and cytokine balance.
 AIM: study was to efficacy tolerability an IL-17A inhibitor (secukinumab) as monotherapy combination with methotrexate patients moderate severe vulgaris.
 MATERIALS AND METHODS: severity assessed by Psoriasis Prevalence Severity Index (Psoriasis Area Index, PASI). To assess damage nail plates hands feet psoriasis, NAPSI index (Nail Index) used. In order quality life a Russian-language version dermatological (DQLI) Patients' before prescribed at 12 weeks treatment. Assessment itching its impact on daily carried out according Prurindex questionnaire.
 RESULTS: All were divided into two groups randomized method. first group included 25 who received secukinumab age category 55 (3067) years. second aged 56 (3469) years treated after initiation (300 mg) 150 mg subcutaneously 15 intramuscularly for 24 weeks. Thus, PASI 90 achieved ― 69%, 100 31% patients; 68%, 32% respectively. both groups, it possible maintain clinical remission (PASI 90) 87.3% throughout year. During there decrease DLQI values from 25.63.7 3.53.1 (p 0.01) 23.33.7 up 3.12.6 group.
 CONCLUSIONS: Treatment vulgaris has shown high safety. Moreover, estimated that comparable effectiveness monotherapy. It been established use significantly improves vulgaris.